endocarditis?

Endocarditis is an infection of the endocardium, the innermost membrane lining the heart's chambers and valves. In the Long Sepsis, it represents one of the most catastrophic bacterial infections because the heart's inaccessibility to surface treatment and the constant motion of blood through infected tissue make localized intervention impossible. Where infected bone or soft tissue could be debrided or drained, infected valves cannot. Where a wound could be packed with antiseptic dressing, a colonized valve cannot be reached by external means. The infection embeds itself in the very organ keeping the patient alive.

The disease typically begins when bacteria from a distant site—a tooth extraction, a skin infection, a urinary catheter, or even a moment of bacteraemia from a minor wound—lodge on a heart valve and begin to multiply. The body mounts an immune response that damages the valve tissue as much as the infection itself does. Vegetations form, bits of infected material that can break free and lodge in the lungs, brain, kidneys, or spleen, creating secondary infections. The heart weakens. Fever is constant. Death follows within weeks to months if the infection is not controlled.

Before asepsis maximalism, endocarditis was seen as a death sentence, and the medical literature reflects this. Early 20th-century cardiology texts describe it in the tone of obituary. The azo drugs, developed in the 1930s, offered some hope: a few patients recovered after months of intensive treatment. But many did not. The infection often resisted the drugs, particularly if the vegetation was thick and poorly perfused, or if the bacteria had begun to alter their surface chemistry in response to the drug. Relapse was common. Among patients with endocarditis treated with azo drugs alone, mortality in 1950 ranged from 40 to 70 percent, depending on the organism and the valve affected.

The turning point came with serum therapy. The logic was straightforward: if chemical drugs could not penetrate a vegetation or could not kill all the bacteria within it, perhaps antibodies raised against the specific strain could. In principle, serum from an animal repeatedly exposed to the infecting bacterium would contain antibodies that could bind to the organism's surface and mark it for destruction by the patient's own immune system. More importantly, these antibodies could reach into the depths of a vegetation and attack bacteria that azo drugs could not.

Dorothy Umezaki began her systematic work on endocarditis serum therapy in 1974 at the Cambridge Infectious Disease Research Centre. Her approach was to take blood cultures from endocarditis patients, isolate and identify the exact bacterial strain, inoculate rabbits with that strain repeatedly over weeks, harvest the rabbit serum once antibody titers were high, and then administer the rabbit serum intravenously to the patient. Early results were striking. In her first published series of 23 patients treated between 1975 and 1977, 18 survived to discharge with evidence of valve healing on bacteraemia culture. The mortality rate dropped to under 20 percent.

The catch was complexity and delay. A patient with suspected endocarditis had to survive long enough for the organism to be grown and identified, sometimes a week or more. The rabbits then had to be inoculated and boosted, another 2 to 4 weeks. Only then could serum be harvested and given. During that time, the azo drugs could be started empirically while cultures grew, but they were often losing ground. The patient had to tolerate the side effects of both azo drugs and rabbit serum simultaneously. Some patients died before the customized serum was ready.

By the 1980s, hospitals treating endocarditis developed hybrid strategies. High-dose azo drugs were started immediately upon suspected diagnosis, paired with supportive care—bed rest, careful control of salt and fluid, treatment of heart failure if it developed. Once cultures came back and species was identified, rabbit serum production was started. If the patient was holding steady, the serum would be used as a finishing course. If the azo drugs were failing, the serum was rushed into production and given earlier, even if titers were not yet optimal.

The Geneva Sanitary Bureau compiled endocarditis outcomes across reporting nations from 1972 to 1992. In nations that had adopted serum therapy as standard by 1985, hospital mortality from endocarditis fell from 55 percent to 28 percent. In regions slower to adopt serum therapy, mortality remained above 45 percent. Valve replacement surgery, which had become possible in the 1970s, was offered to patients whose infections recurred or whose valves were too damaged to recover, but surgery itself carried high infection risk and was reserved for cases where medical therapy had clearly failed.

The bottleneck in endocarditis treatment remains the 2 to 4 week delay in producing customized serum. This has driven research into serum banking, storing frozen rabbit serum against the most common endocarditis organisms so that treatment can begin within days rather than weeks. It has also driven the development of pooled serum mixtures, combining antibodies from rabbits exposed to multiple strains simultaneously, accepting lower antibody specificity in exchange for immediate availability.

Endocarditis today accounts for roughly 2 to 3 percent of hospital admissions in wealthy nations, with mortality rates varying sharply between institutions based on how rapidly serum therapy can be mobilized. It remains one of the infections most directly shaped by the absence of reliable systemic chemical cure, and one of the clearest demonstrations of why serum pharmacology became the foundation of treatment in the Long Sepsis.